Venture Certified
| 연구개발유형 | 2021-08-04 ~ 2024-08-03 | 20210804020004 | 2021-08-04 |
| 연구개발유형 | 2024-08-04 ~ 2027-08-03 | 20240820020011 | 2021-08-04 |
Revenue CAGR +36.7%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.2B | 0.0B | 0.1B |
| Operating Profit | -12.6B | -12.0B | -11.3B |
| Net Profit | -14.7B | -13.6B | -11.2B |
| Total Assets | 8.2B | 10.8B | 3.6B |
| Total Liabilities | 23.7B | 24.2B | 15.3B |
| Total Equity | -15.5B | -13.4B | -11.7B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -13B
3 Consecutive Years of Net Loss
▲ 264.1%
▼ 8.3%
▲ 97.0%
▲ 1.8%
▼ 4.1%
| Name | Position | Role |
|---|---|---|
| 황성환 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "인천광역시 서구",
"ceo_name": "황성환",
"certificate": [
{
"cert_number": "20210804020004",
"changes": "",
"disclosure_date": "2021-08-04",
"first_cert_date": "2021-08-04",
"no": "1",
"type": "연구개발유형",
"valid_period": "2021-08-04 ~ 2024-08-03"
},
{
"cert_number": "20240820020011",
"changes": "",
"disclosure_date": "2024-08-20",
"first_cert_date": "2021-08-04",
"no": "2",
"type": "연구개발유형",
"valid_period": "2024-08-04 ~ 2027-08-03"
}
],
"company_name": "(주)스마트셀랩",
"corp_no": "120111-*******",
"financials": {
"2022": {
"capital_stock": 2485000000,
"cost_of_sales": 0,
"current_assets": 104359000,
"current_liabilities": 1369494000,
"gross_profit": 11145000,
"net_income": -1120841000,
"net_income_bs": -1120841000,
"non_current_assets": 256310000,
"non_current_liabilities": 161301000,
"non_operating_expenses": 34707000,
"non_operating_income": 43575000,
"operating_profit": -1129709000,
"revenue": 11145000,
"sga_expenses": 1140854000,
"total_assets": 360669000,
"total_equity": -1170126000,
"total_liabilities": 1530795000
},
"2023": {
"capital_stock": 2552500000,
"cost_of_sales": 0,
"current_assets": 599778000,
"current_liabilities": 2194264000,
"gross_profit": 302000,
"net_income": -1361964000,
"net_income_bs": -1361964000,
"non_current_assets": 484254000,
"non_current_liabilities": 225160000,
"non_operating_expenses": 175353000,
"non_operating_income": 17175000,
"operating_profit": -1203786000,
"revenue": 302000,
"sga_expenses": 1204088000,
"total_assets": 1084032000,
"total_equity": -1335392000,
"total_liabilities": 2419424000
},
"2024": {
"capital_stock": 3838749000,
"cost_of_sales": 0,
"current_assets": 255965000,
"current_liabilities": 2074027000,
"gross_profit": 20839000,
"net_income": -1469561000,
"net_income_bs": -1469561000,
"non_current_assets": 568717000,
"non_current_liabilities": 300013000,
"non_operating_expenses": 221955000,
"non_operating_income": 15505000,
"operating_profit": -1263111000,
"revenue": 20839000,
"sga_expenses": 1283950000,
"total_assets": 824682000,
"total_equity": -1549358000,
"total_liabilities": 2374040000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "줄기세포 배양액, 세포치료제",
"phone": "032-715-****",
"years": [
2024,
2023,
2022
]
}